NovoCure (NASDAQ:NVCR – Free Report) had its price target increased by HC Wainwright from $22.00 to $24.00 in a research report released on Friday, Benzinga reports. They currently have a neutral rating on the medical equipment provider’s stock.
NVCR has been the subject of a number of other research reports. Piper Sandler restated an overweight rating and set a $28.00 target price (up previously from $25.00) on shares of NovoCure in a research report on Wednesday, April 10th. Wedbush restated an outperform rating and set a $24.00 price objective on shares of NovoCure in a research report on Thursday, July 25th. Wells Fargo & Company reduced their target price on NovoCure from $49.00 to $42.00 and set an overweight rating on the stock in a report on Wednesday, April 3rd. Finally, Evercore ISI raised their price target on NovoCure from $14.50 to $20.00 and gave the company an in-line rating in a report on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, NovoCure presently has a consensus rating of Moderate Buy and a consensus price target of $31.88.
View Our Latest Report on NovoCure
NovoCure Stock Performance
NovoCure (NASDAQ:NVCR – Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.09. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. The business had revenue of $150.40 million for the quarter, compared to analysts’ expectations of $135.83 million. During the same period last year, the firm earned ($0.54) earnings per share. The business’s quarterly revenue was up 19.3% on a year-over-year basis. Equities analysts anticipate that NovoCure will post -1.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On NovoCure
A number of hedge funds have recently added to or reduced their stakes in the stock. Ridgewood Investments LLC bought a new stake in shares of NovoCure during the second quarter valued at approximately $28,000. Fifth Third Bancorp bought a new stake in NovoCure during the 2nd quarter valued at $43,000. GAMMA Investing LLC lifted its holdings in shares of NovoCure by 278.0% in the 1st quarter. GAMMA Investing LLC now owns 2,880 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 2,118 shares during the period. Nisa Investment Advisors LLC bought a new position in shares of NovoCure during the 2nd quarter worth $48,000. Finally, Versant Capital Management Inc increased its stake in shares of NovoCure by 2,917.0% during the second quarter. Versant Capital Management Inc now owns 3,017 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 2,917 shares during the period. 84.61% of the stock is currently owned by institutional investors.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Read More
- Five stocks we like better than NovoCure
- Manufacturing Stocks Investing
- Survey: Top 175 Fittest Retirement Locations in America
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Dividend Capture Strategy: What You Need to Know
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.